ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 912

Clinical Features Associated with Progression of Knee Radiographic Osteoarthritis: Data From the Osteoarthritis Initiative

Michelle S. Yau1, Laura Yerges-Armstrong1, Braxton D. Mitchell1 and Marc C. Hochberg2, 1Departments of Medicine and Epidemiology & Public Health, University of Maryland School of Medicine, Baltimore, MD, 2Department of Medicine, University of Maryland, Baltimore, MD

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Knee, osteoarthritis and prognostic factors

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease II

Session Type: Abstract Submissions (ACR)

Background/Purpose:  A better understanding of the factors associated with structural progression of knee osteoarthritis (OA) may help identify individuals not only at risk for more rapid OA progression who can benefit from early intervention, but also help classify high-risk OA patients for inclusion in clinical trials of new treatments. Using the complete 4-year follow-up data from the Osteoarthritis Initiative (OAI), we tested baseline measures from six domains [1) knee examination, 2) anthropometric characteristics, 3) sociodemographic characteristics, 4) medical and family history, 5) physical functioning, and 6) self-reported pain and symptoms] for their association with radiographic knee OA (RKOA) progression.

Methods:  Subjects with evidence of RKOA in one or both knees at baseline and with at least 1 follow-up exam over the 4-year period (n = 3,204) were eligible for analysis; knees with end-stage disease were excluded from the analysis. We defined RKOA progression as an increase in Kellgren-Lawrence (KL) grade or osteophyte score or joint space narrowing score. We used Cox regression models to test the association of individual level measures with RKOA progression, adjusting for age, gender, and race. Within each of the six domains, we performed univariate and multivariable stepwise analyses. Significant predictors from all domain-level multivariable models were then included in an overall multivariable analysis with stepwise selection. We also conducted knee-specific analyses with the same approach, but included a robust sandwich estimate of the covariance matrix to account for non-independence of two knees within an individual. 

Results:  51% of subjects with baseline RKOA (KL grade 1-3) experienced RKOA progression in one or both knees. Progressors were 58% female, 19% Black, and had mean (SD) age of 61 (9) years and mean body mass index of 29 (5) kg/m2. Subjects with no RKOA progression had a similar profile. In the multivariable model for each domain, the following baseline factors were found to be significantly associated with RKOA progression: knee joint effusion, pain on flexion, patellofemoral crepitus, patellar grind, and flexion contracture; number of hand bony enlargements, history of knee injury, and use of analgesics; repeated chair stand pace, 400-meter walk pace, and pain during 400-meter walk; KOOS sports and recreational activities score and KOOS symptoms score. Similar results were obtained with the knee-specific analyses with the additional significant finding of KOOS pain score. Final, overall multivariable models for the individual and knee-specific analyses are presented in Table 1.

Conclusion:  Out of the six domains investigated, four domains yielded significant measures associated with RKOA progression. These measures may help identify individuals at increased risk of RKOA progression who may benefit from early intervention. 

Table 1. Hazard Ratios for Associations with RKOA Progression

Hazard Ratio (95% CI)

Domain

Parameter

Individual-level

Knee-specific

Knee exam

Knee joint effusion, bulge sign positive

1.34 (1.14-1.58)

1.29 (1.09-1.52)

Patello-femoral crepitus

1.58 (1.36-1.83)

1.39 (1.22-1.58)

Knee flexion contracture

1.02 (1.00-1.04)

1.02 (1.00-1.04)

Knee flexion pain/tenderness

—

1.26 (1.06-1.49)

Medical and family history

Number of bony enlargements in hands

1.03 (1.00-1.05)

1.04 (1.01-1.06)

History of knee injury

—

1.27 (1.11-1.46)

Physical functioning

Pain during 400-meter walk

1.33 (1.12-1.59)

—

Self-reported pain/symptoms

KOOS sports/recreational activities score

0.99 (0.99-0.99)

0.99 (0.99-1.00)

KOOS Pain Score

—

0.99 (0.99-1.00)

Adjusted covariates

Black race

1.04 (0.86-1.26)

1.00 (0.84-1.18)

Asian race

0.74 (0.27-2.00)

0.75 (0.28-2.00)

Other race

0.63 (0.33-1.22)

0.72 (0.38-1.36)

Male gender

0.94 (0.81-1.09)

0.93 (0.81-1.07)

Age

1.00 (0.99-1.01)

1.00 (0.99-1.01)


Disclosure:

M. S. Yau,
None;

L. Yerges-Armstrong,
None;

B. D. Mitchell,
None;

M. C. Hochberg,

Abbott Laboratories, Astra-Zeneca, Bioiberica S.A., Eli Lilly Inc., Genentech/Roche, Merck Inc., Novartis Pharma A.G., Pfizer Inc., Stryker LLC, Xoma.,

5.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-features-associated-with-progression-of-knee-radiographic-osteoarthritis-data-from-the-osteoarthritis-initiative/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology